Published in Stat Med on July 30, 2003
Augmented designs to assess immune response in vaccine trials. Biometrics (2006) 2.78
Causal Vaccine Effects on Binary Postinfection Outcomes. J Am Stat Assoc (2006) 1.83
Principal stratification--uses and limitations. Int J Biostat (2011) 1.59
Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl. Int J Biostat (2011) 1.40
Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine (2009) 1.24
Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization. J Am Stat Assoc (2007) 1.11
Semiparametric estimation of treatment effects given base-line covariates on an outcome measured after a post-randomization event occurs. J R Stat Soc Series B Stat Methodol (2007) 1.10
Does Finasteride Affect the Severity of Prostate Cancer? A Causal Sensitivity Analysis. J Am Stat Assoc (2008) 1.10
Sensitivity analyses comparing time-to-event outcomes only existing in a subset selected postrandomization and relaxing monotonicity. Biometrics (2010) 1.08
A simple method for principal strata effects when the outcome has been truncated due to death. Am J Epidemiol (2011) 1.04
Identification and estimation of survivor average causal effects. Stat Med (2014) 0.98
Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data. Biostatistics (2009) 0.93
Randomization-Based Inference within Principal Strata. J Am Stat Assoc (2011) 0.91
Nonparametric Bounds and Sensitivity Analysis of Treatment Effects. Stat Sci (2014) 0.88
Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand. J Acquir Immune Defic Syndr (2009) 0.80
Sharpening bounds on principal effects with covariates. Biometrics (2013) 0.80
Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. J Acquir Immune Defic Syndr (2007) 0.79
THE POTENTIAL FOR BIAS IN PRINCIPAL CAUSAL EFFECT ESTIMATION WHEN TREATMENT RECEIVED DEPENDS ON A KEY COVARIATE. Ann Appl Stat (2011) 0.77
Causal analysis of ordinal treatments and binary outcomes under truncation by death. J R Stat Soc Series B Stat Methodol (2016) 0.75
A Bayesian approach to estimating causal vaccine effects on binary post-infection outcomes. Stat Med (2015) 0.75
HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet (2008) 8.37
Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity (2004) 6.89
Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst (2002) 5.57
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol (2009) 3.29
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS One (2008) 3.05
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine (2006) 2.89
Denoising array-based comparative genomic hybridization data using wavelets. Biostatistics (2005) 2.56
Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med (2008) 2.50
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol (2006) 2.32
Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol (2007) 2.13
Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol (2010) 2.02
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood (2012) 1.93
Statistical positivity criteria for the analysis of ELISpot assay data in HIV-1 vaccine trials. J Immunol Methods (2006) 1.76
Ontogeny of Toll-like receptor mediated cytokine responses of human blood mononuclear cells. PLoS One (2010) 1.66
Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms. J Clin Oncol (2010) 1.66
Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. J Infect Dis (2009) 1.58
Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials. Cytometry A (2008) 1.54
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica (2012) 1.53
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res (2007) 1.53
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood (2008) 1.45
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer (2006) 1.42
Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med (2008) 1.40
What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis (2003) 1.38
Statistical considerations for the design and analysis of the ELISpot assay in HIV-1 vaccine trials. J Immunol Methods (2004) 1.37
The clustering of regression models method with applications in gene expression data. Biometrics (2006) 1.32
Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev Res (Phila) (2013) 1.31
Equivalence of ELISpot assays demonstrated between major HIV network laboratories. PLoS One (2010) 1.30
Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol (2005) 1.24
Mapping HIV-1 vaccine induced T-cell responses: bias towards less-conserved regions and potential impact on vaccine efficacy in the Step study. PLoS One (2011) 1.16
Chromosomal instability in Barrett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev (2006) 1.12
How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J Virol (2005) 1.07
Direct inference of SNP heterozygosity rates and resolution of LOH detection. PLoS Comput Biol (2007) 1.06
Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol (2009) 1.06
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens. Stat Commun Infect Dis (2011) 1.06
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica (2012) 1.05
Advancing the high throughput identification of liver fibrosis protein signatures using multiplexed ion mobility spectrometry. Mol Cell Proteomics (2014) 1.04
Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. Blood (2009) 1.01
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3. Blood (2013) 1.00
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood (2013) 0.99
Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays. Cancer Res (2005) 0.99
Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'. Stat Med (2009) 0.94
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood (2008) 0.94
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1. Clin Cancer Res (2012) 0.91
First thalidomide clinical trial in multiple myeloma: a decade. Blood (2008) 0.90
HIV-1 vaccine-induced T-cell responses cluster in epitope hotspots that differ from those induced in natural infection with HIV-1. PLoS Pathog (2013) 0.90
Towards prediction of degenerate CTL epitope recognition. Hum Vaccin (2007) 0.89
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma. Haematologica (2013) 0.87
Statistical evaluation of HIV vaccines in early clinical trials. Contemp Clin Trials (2006) 0.86
Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. Vaccine (2011) 0.85
Do scarce targets or T killers control primary HIV infection? J Theor Biol (2002) 0.85
Finding gene clusters for a replicated time course study. BMC Res Notes (2014) 0.83
What's the matter with HIV-directed killer T cells? J Theor Biol (2002) 0.82
Endpoints in vaccine trials. Stat Methods Med Res (2004) 0.82
HIV fragment gag vaccine induces broader T cell response in mice. Vaccine (2011) 0.81
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol (2013) 0.81
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One (2013) 0.81
Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica (2008) 0.79
[Randomized trial of breast self-examination in 266,064 women in Shanghai]. Zhonghua Zhong Liu Za Zhi (2005) 0.79
On simulating strongly interacting, stochastic population models. II. Multiple compartments. Math Biosci (2004) 0.78
On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials. PLoS Comput Biol (2006) 0.78
Identifying trait clusters by linkage profiles: application in genetical genomics. Bioinformatics (2008) 0.77
On simulating strongly-interacting, stochastic population models. Math Biosci (2004) 0.76
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med (2014) 0.75
A Comparison of Testing Parameters and the Implementation of a Group Sequential Design for Equivalence Studies Using Paired-sample Analysis. Stat Biopharm Res (2012) 0.75